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Abstract
Background: The main hypothesis of this study is that neutral pH, low glucose degradation product (GDP)
peritoneal dialysis (PD) fluid better preserves residual renal function in PD patients over time compared with
conventional dialysate.
Methods/Design: Inclusion criteria are adult PD patients (CAPD or APD) aged 18-81 years whose first dialysis was
within 90 days prior to or following enrolment and who have a residual GFR ≥ 5 ml/min/1.73 m
2, a urine output ≥
400 ml/day and an ability to understand the nature and requirements of this trial. Pregnant or lactating patients or
individuals with an active infection at the time of enrolment, a contra-indication to PD or participation in any other
clinical trial where an intervention is designed to moderate rate of change of residual renal function are excluded.
Patients will be randomized 1:1 to receive either neutral pH, low GDP dialysis solution (Balance®) or conventional
dialysis solution (Stay.safe®) for a period of 2 years. During this 2 year study period, urinary urea and clearance
measurements will be performed at 0, 3, 6, 9, 12, 18 and 24 months. The primary outcome measure will be the
slope of residual renal function decline, adjusted for centre and presence of diabetic nephropathy. Secondary
outcome measures will include time from initiation of peritoneal dialysis to anuria, peritoneal small solute
clearance, peritoneal transport status, peritoneal ultrafiltration, technique survival, patient survival, peritonitis rates
and adverse events. A total of 185 patients has been recruited into the trial.
Discussion: This investigator-initiated study has been designed to provide evidence to help nephrologists
determine the optimal dialysis solution for preserving residual renal function in PD patients.
Trial Registration: Australian New Zealand Clinical Trials Registry Number: ACTRN12606000044527
Background
During the past 30 years, peritoneal dialysis (PD) has
become an established form of treatment for patients
with end-stage renal disease [1,2]. Most published obser-
vational cohort studies suggest that the medium-term
survival (up to 3 to 4 years) of patients treated with PD
is at least comparable, and possibly superior, to that of
patients receiving haemodialysis (HD) [3-7]. However,
PD is associated with a higher rate of technique failure
than HD. As rates of peritonitis have fallen in recent
years, an increasing proportion of technique failure is
attributable to alteration in membrane function whereby
high solute transport is associated with loss of ultrafil-
tration capacity [8]. Unfortunately, the time sequence of
loss of peritoneal ultrafiltration capacity and loss of resi-
dual renal function and urineo u t p u tc o i n c i d ew h e r e b y
the two significantly limit an individual patient’s capacity
to control solute and volume homeostasis.
A large body of basic research in animal models and
peritoneal cell culture systems has suggested that a
major contributor to the high technique failure rate is
the bioincompatible nature of conventional PD fluids.
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as well as having a pro-fibrotic effect on the peritoneal
membrane [9-11]. Conventional PD fluids are consid-
ered “unphysiological,” based on their acidic pH (5.0-
5.8), high lactate concentrations (30-40 mmol/L), high
osmolality (320-520 mOsm/kg), high glucose concentra-
tions (31-236 mmol/L), and contamination by glucose
degradation products (GDP) generated during the heat
sterilization process [12]. Such solutions reduce the via-
bility and growth of peritoneal mesothelial cells and
fibroblasts in vitro, alter the turnover of structural col-
lagen, and modify the homeostatic balance of cytokines
and growth factors [11,13,14]. The viability and function
of peritoneal phagocytic cells, such as macrophages, are
also impaired by standard peritoneal fluids [12,13].
Moreover, experimental and clinical exposure of the
peritoneal membrane to conventional PD solutions
engenders significant histopathological changes over
time, including loss of the surface mesothelial cell layer,
thickening of the submesothelial compact zone and the
development of a progressive vasculopathy [15,16]. Most
of these adverse effects of dialysate on the peritoneal
membrane appear to be accounted for by acidic pH and
high concentrations of GDPs, since they were largely
abrogated in in vivo studies by the use of neutral-buf-
fered, low GDP fluids [11,12,17,18]. In addition to their
direct cytotoxicity and stimulation of inflammatory cyto-
kine production, GDPs promote the formation and
deposition of advanced glycation end-products (AGEs)
in the peritoneal membrane, which in turn correlates
with peritoneal membrane fibrosis and histopathology
[19,20].
All of the main industry manufacturers of PD solu-
tions have now released to the market solutions that
have low GDP levels (and, incidentally, a neutral or near
neutral solution pH). Recent clinical trials with these
solutions attest to their lower cytotoxicity for mesothe-
lial cells and their use is also associated with less evi-
dence of local peritoneal inflammation [21,22]. However,
evidence of a beneficial effect on the morphological and
functional changes associated with long-term exposure
to PD fluids is not yet available. Nevertheless, a large,
retrospective, observational cohort study in Korea
[23,24] has demonstrated an association between the
use of neutral pH, lactate-buffered, low GDP fluids and
superior survival, although th i sf i n d i n gw a sp o t e n t i a l l y
limited by indication bias with residual confounding
[25].
An alternative means by which the use of neutral pH,
low GDP solutions might favourably impact PD patient
outcomes relates to improved preservation of native kid-
ney function. In the literature relating to survival of PD
patients, there is overwhelming evidence that survival is
determined more by residual renal function than by
peritoneal function [26-28]. A multi-centre, open-label,
prospective, randomized crossover study of conven-
tional, acidic, lactate-buffered fluid with pH neutral, lac-
tate-buffered, low GDP fluid in 86 prevalent CAPD
patients from 22 centres in 11 European countries [22]
demonstrated increases in renal urea and creatinine
clearances over a 12 week period. Subsequently, several
small, short-term, randomised controlled trials reported
that neutral pH, low GDP fluids were associated with
either a neutral [29,30] or beneficial [31] effect on resi-
dual renal function. However, these studies were limited
by insufficient statistical power, short-term follow-up
and single centre designs.
The current multi-centre, randomised controlled study
is designed to ask whether neutral pH, low GDP perito-
neal dialysis fluid better preserves residual renal function
in PD patients over a 2 year period compared with con-
ventional dialysate.
Methods/Design
Ethics approval for the balANZ trial has been obtained
from the local Institutional Ethics Committee in all par-
ticipating centres prior to study initiation and patient
enrolment. The study will be performed in accordance
with the 2000 Edinburgh, Scotland Revision of the
Declaration of Helsinki, the National Health and Medi-
cal Research Committee (NHMRC) Statement on
Human Experimentation, Joint NHMRC/AVCC State-
ment and Guidelines on Research Practice, applicable
ICH guidelines and the Therapeutic Goods Administra-
tion (TGA) - Note for guidance on good clinical prac-
tice (CPMP/ICH/135/95) annotated with TGA. All
patients are to provide written informed consent before
any trial related procedure can occur.
Participants
Patients must fulfill all of the following conditions in
order to be considered for the study enrolment or parti-
cipation:
￿ Male or female patients, age ≥ 18 years and < 81
years
￿ Diagnosis of end stage renal disease
￿ First treatment for ESRD by any dialysis modality
within 90 days prior to or following enrolment
(patients may be enrolled prior to commencing first
treatment if there is clear indication that the treat-
ment modality is CAPD or APD and they consent in
advance to enter the study)
￿ Selected to be treated by CAPD or APD
￿ Residual GFR at enrolment ≥ 5 ml/min/1.73 m
2
￿ Urine volume per day ≥ 400 ml at enrolment
￿ Written informed consent before any trial related
activities
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of this trial
Patients with any of the following conditions will be
excluded from study enrolment:
￿ Prognosis for survival less than 12 months
￿ Pregnancy or lactation period
￿ History of malignancy other than a successfully
and completely treated cutaneous squamous cell or
basal cell carcinoma or carcinoma in-situ of the cer-
vix within the last 5 years
￿ Any acute infections at the time of enrolment into
the study
￿ Any disease of the abdominal wall, such as injury
or surgery, burns, hernia, dermatitis, that in the opi-
nion of the Investigator would preclude the patient
from being able to have peritoneal dialysis
￿ Any inflammatory bowel diseases (Crohns’ disease,
ulcerative colitis or diverticulitis) that in the opinion
of the Investigator would preclude the patient from
being able to have peritoneal dialysis
￿ Any intra-abdominal tumours or intestinal
obstruction
￿ Any patient with active serositis
￿ Any condition (mental or physical) that would
interfere with the patient’s ability to comply with the
study protocol
￿ Known or suspected allergy to trial product or
related products
￿ Participation in any other clinical trial where an
intervention is designed to moderate rate of change
of residual renal function
Study Design
The study is an investigator-initiated, prospective,
open label, randomized, placebo-controlled phase 4
trial. Patients will be randomised to one of two treat-
ment groups in equal proportion (Fig. 1). To ensure
adequate concealment of allocation, the randomization
will be performed using a central computer and web-
based link to the central database. Stratification will
occur according to centre and the presence or
absence of diabetes mellitus. Patients will be recruited
from 16 centres across Australia, New Zealand and
Singapore.
Experimental Intervention
Patients in the experimental arm will receive neutral pH,
lactate-buffered, low GDP Balance® solutions in Biofine®,
platicizer-free solution bags provided by Fresenius Medi-
cal Care. The chemical composition of this fluid is
shown in Table 1.
Control Intervention
Patients in the control arm will receive conventional,
standard, lactate-buffered PD solutions (Stay.safe®) in
Biofine®, platicizer-free solution bags provide by Frese-
nius Medical Care. The chemical composition of this
fluid is shown in Table 1.
Concurrent Treatments
Patients in each trial arm will undergo standard man-
agement, as per local PD unit protocols. Icodextrin is
permitted in both the control and experimental groups.
Blinding
This is an open-label study. Therefore, after randomiza-
tion, the investigator, pharmacist and patient will be
aware of which peritoneal dialysis solution the patient
will be receiving.
Outcome Measures
The primary outcome measure is slope of residual renal
function (RRF) decline measured as GFR (mean of renal
urea and creatinine clearances) over time (follow-up 24
months).
Secondary outcomes will include:
a. Time from initiation of PD to anuria (daily urine
volume less than 100 ml).
b. Peritoneal small solute clearance (Kt/V, creatinine
clearance)
c. Peritoneal transport status (PET D/P creatinine
and D/Do glucose)
d. Peritoneal ultrafiltration capacity (UF[ml/day] and
nUF[ml/day/m
2])
e. Technique survival
f. Patient survival
g. Peritonitis rates
h. Adverse events
Clinical Assessment of Outcome
Residual renal function will be measured from timed urine
collections as the arithmetic mean of urinary urea and
creatinine clearance [32]. Data will be collected at the start
of the study-phase (baseline week 0, visit 0), and at Month
3 and then at 3 monthly intervals thereafter (total 6 mea-
surements) in the first 12 months. Data will be collected at
6 monthly intervals if treatment extends into the second
year. A maximum of 8 visits will be required for the study.
Visit windows will be ± 1 week in the first year and ± 2
weeks in the second year of treatment.
Monitoring for Adverse Events
The number and proportion of subjects who report treat-
ment-emergent adverse events will be summarized for
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events that start on or after Day 0 of the study [that is the
first day of Study Drug administration], and were not pre-
sent at baseline, or were present at baseline, but increased
in severity after the start of the study. The Medical Dic-
tionary for Regulatory Activities [MedDRA] Terminology
will be used to classify all adverse events with rESAect to
System Organ Class [SOC], high level group term
(HLGT), and preferred term. Balance®a n dstay*safe®s o l u -
tions are already registered and marketed PD solutions in
terms of their composition and intended use.
Sample Size Calculations
A prospective sample size calculation was based on
information collected from earlier phase work, with an
anticipated rate of decline of residual renal function
(RRF) with Balance at -0.044 ml/min/1.73 m
2/month
compared with stay safe at -0.111 ml/min/1.73 m
2/
month, with a common standard deviation of 0.219 ml/
min/1.73 m
2/month. The estimated sample size per arm
based on this information was 168 (total population
336), giving the study 80% power to detect a difference
in slope of RRF versus time of 0.067.
Figure 1 Schema for the balANZ Trial.
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Commencing in November 2004, it was initially antici-
pated that trial recruitment would be completed by
December 2008, with final follow-up completed by
December 2010. As of 1 October 2008, only 185
patients had been recruited into the study, accounting
for 55% of the target. A decision was therefore made by
the Trial Management Committee to halt further
recruitment and to continue the trial until the last
patient enrolled had been followed for 2 years (31
August 2010). Results will be analysed and reported in
early 2011. Based on the final number recruited (185),
the study has 80% power to detect a difference in RRF
versus time of 0.091 ml/min/1.73 m
2/month.
Statistical Analyses
A mixed effects General Linear Model will be fitted with
residual renal function as the outcome variable and
treatment group, time, centre and presence of diabetic
nephropathy (Yes/No) as fixed effects terms. Patients
will be fitted as a ‘random’ term in the model. In this
w a y ,t h em o d e lw i l lp r o v i d ee s t i m a t e so ft h er a t eo f
decline in RRF (the slope) for each patient and an
appropriate framework to model the covariance struc-
ture for repeated measures. From this, an overall esti-
mate of the rate of decline in each treatment group will
be determined, corrected for centre and presence of dia-
betic nephropathy. The estimated slopes for the treat-
ment groups will be compared via a t-test. The data will
be assumed to be normally distributed and to decline in
a linear fashion. However, the assumptions of homoge-
neity of variance and normality of residuals will be
checked. Major departures from these assumptions will
result in the employment of appropriate non-parametric
tests or transformation. This analysis will be performed
for both the month 12 and month 24 reporting efforts
on an intention-to-treat basis. Secondary time to event
analyses will be analysed by multivariate Cox propor-
tional hazards model analyses with treatment group,
centre, presence of diabetic nephropathy and baseline
renal function as covariates. P values < 0.05 will be con-
sidered significant.
Discussion
This investigator-initiated, multicentre Australian, New
Zealand and Singapore study has been designed to pro-
vide evidence to help nephrologists and their PD
patients better determine the optimal dialysis solution
for preserving residual renal function. Given that
numerous studies have demonstrated that PD patients
with rapid residual renal function decline are at signifi-
cantly increased risk of mortality [26-28], novel treat-
ments for preserving residual renal function in this
group (such as with the use of neutral pH, low GDP
dialysis fluids) may represent an important strategy for
improving clinical outcomes in PD patients. The multi-
centre nature of the trial will greatly enhance its
generalisability.
One of the significant difficulties encountered to date
with the running of the trial has been slower than antici-
pated recruitment. Some of the reasons for this included
initial delays with being able to accommodate patients
receiving APD as well as a reluctance by some clinicians
to allow patients to be randomised to conventional dialy-
sate because of a firmly held belief that such fluids were
inferior to “biocompatible” fluids. The hurdle encoun-
tered in recruiting to target in the balANZ trial due to
the fact that use of biocompatible fluids is becoming
standard in Australasia and many other parts of the
world without high level supporting evidence, suggest
that it may be extremely difficult for a future larger ran-
domised controlled trial to be mounted if the present
study does not prove to be definitive. Nevertheless, it is
extremely important to establish high level clinical evi-
dence for the benefits of “biocompatible” fluids compared
to conventional dialysates, since they are appreciably
more expensive and consequently have important impli-
cations for the allocation of limited health resources. Sim-
ply relying on biological plausibility and the results of
observational cohort studies is fraught with peril due to
confounding by indication and other biases. Indeed, there
are numerous examples in nephrology practice where
firm clinical guideline recommendations based on opi-
nion supported by observational studies have been subse-
quently over-turned by the findings of randomised
controlled clinical trials and systematic reviews (viz. peri-
toneal dialysis small solute clearance augmentation,
serum cholesterol lowering and anaemia correction).
Table 1 Comparison of the chemical composition of the
experimental (Balance®) and control (Stay.safe®) fluids
used in the balANZ trial
Component Experimental
(Balance®)
Control
(Stay.safe®)
Sodium (mmol/L) 134 134
Chloride (mmol/L) 100.5 102.5
Lactate (mmol/L) 35 35
Bicarbonate (mmol/L) 2 0
pH 7 5.5
Glucose (g/L) 15-42.5 15-42.5
3-deoxyglucosone (μmol/L) 42-60 173-324
Methylglyoxyl (μmol/L) < 1 6-10
Acetaldehyde (μmol/L) < 2 152-182
Formaldehyde (μmol/L) < 3 7-13
Calcium (mmol/L) 1.25 1.25
Magnesium (mmol/L) 0.5 0.5
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over half that required to provide adequate statistical
power according to prospective sample size calculations,
it will nevertheless be the largest randomised controlled
clinical trial to date of “biocompatible” versus conven-
tional dialysis fluids in PD patients and will be twice the
size of the next largest, published controlled trial [29].
Whilst the reduced final sample size of 185 will ulti-
mately result in decreased statistical power, the study
will still have 80% power to detect a difference in RRF
decline of 0.091 mL/min/1.73 m
2/month. This detect-
able difference compares favourably with the differences
in RRF decline reported between Balance® and Stay.safe®
fluids in other trials, such as Euro-Balance (0.21 mL/
min/1.73 m
2/month over 3 months) [22] and Balnet
(0.80 mL/min/1.73 m
2/month over 12 months) [31]. In
t h ee v e n to fan e g a t i v es t u d yf i n d i n g ,w h i c hm i g h t
potentially reflect a type 2 statistical error, the ability to
detect a smaller benefit of biocompatible fluids on resi-
dual renal function decline could still be possible as a
result of incorporation of the balANZ trial data into a
meta-analysis of all randomised controlled trials of bio-
compatible fluids versus conventional biocompatible
fluids currently being undertaken by the Cochrane
Renal Group [33]. Such a systematic review may also
help to determine whether biocompatible fluids influ-
ence patient-level outcomes, such as technique survival
and patient survival, for which all studies to date have
been significantly underpowered.
In conclusion, demonstration by the balANZ study of
a significant improvement in residual renal function
decline with neutral pH, low GDP fluids will provide
clinicians with an important new strategy for effectively
treating PD patients. On the other hand, a negative
study will dissuade clinicians from prescribing more
expensive fluids for no clear clinical benefit.
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